新云社 update: The global pivotal Phase III POLARIS-AD trial of oral Alzheimer’s drug AR1001 will report topline results as an oral presentation at the 19th Clinical Trials on Alzheimer’s Disease congress (CTAD 2026), held November 16-19 in Boston, with the data first disclosed on November 16. Fosun Pharma holds regional licensing rights and exclusive options in core global markets for the oral disease-modifying candidate.
AR1001 Alzheimer’s Phase III Topline Data to Debut at CTAD 2026
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
37m ago
Bitcoin falls to intraday low of $55,555.55 on Binance
41m ago
Bit Digital Deposits 16,639 ETH to Galaxy Digital, Sitting on $237M Unrealized Loss
45m ago
JackYi: Market Drop Tied to Global Financial Risk, Not Crypto Data
48m ago
Ethereum Falls Out of Top 100 Global Assets by Market Cap
58m ago
Two Traders Liquidated for Combined $36.09M in BTC, ETH
1h ago
Kiyosaki Says He’ll Wait for Bitcoin Bottom Before Buying




